Actively Recruiting
AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
Led by Henan Cancer Hospital · Updated on 2024-02-21
43
Participants Needed
1
Research Sites
283 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
AK104, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of AK104 with chemotherapy as neoadjuvant and adjuvant therapy for patients with resectable stage II-IIIA NSCLC.
CONDITIONS
Official Title
AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Previously untreated and pathologically confirmed resectable Stage II-IIIA non-small cell lung cancer (NSCLC)
- At least one measurable lesion per RECIST 1.1 assessed by investigator
- Adequate organ function
You will not qualify if you...
- Mixed non-small cell lung cancer and small cell lung cancer histology
- Other active malignancies within 3 years prior to enrollment
- Known active autoimmune diseases
- Use of immunosuppressive agents within 14 days prior to the first dose of study treatment
- Presence of other uncontrolled serious medical conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Henan Cancer Hospital
Zhengzhou, Henan, China, 450003
Actively Recruiting
Research Team
H
Huijuan Wang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here